The copper-free form of the glycyl-L-histidyl-L-lysine tripeptide that retains significant biological activity in wound healing and tissue regeneration without requiring copper chelation.
Sourced from Ascension Peptides. Verified purity, third-party tested. COA included.
Buy Now →GHK — formally glycyl-L-histidyl-L-lysine — is a naturally occurring tripeptide found in human plasma, urine, and saliva. It was first isolated and characterized by Dr. Loren Pickart in the early 1970s from a fraction of human albumin that displayed tissue regenerative properties. While GHK is perhaps most widely known today as the copper-binding form GHK-Cu (copper peptide), the free tripeptide GHK without copper coordination is itself a biologically active molecule with a strikingly distinct and arguably even more interesting mechanistic profile. This content focuses specifically on copper-free GHK.
The distinction between GHK and GHK-Cu matters because the two forms of the molecule do genuinely different things at the molecular level. GHK-Cu’s copper-dependent activities — superoxide dismutase-like antioxidant capacity, VEGF promotion, collagen crosslinking facilitation — are well established and depend on the Cu(II) ion coordinated at the histidine imidazole and terminal amine. Copper-free GHK, by contrast, engages biology primarily through direct peptide-receptor or peptide-DNA interactions that do not require metal coordination. Understanding these copper-independent mechanisms is essential for researchers who want to study GHK’s gene regulatory properties in isolation from copper chemistry.
What has made copper-free GHK increasingly compelling to researchers is the work of Dr. Pickart and colleagues applying genome-wide expression analysis to GHK-treated cells. Their analyses found that GHK — even without copper — modulates the expression of over 4,000 human genes, representing roughly one-fifth of the entire annotated genome. The patterns of gene expression change are striking: GHK tends to upregulate genes associated with tissue repair, stem cell renewal, and metabolic health while downregulating genes associated with inflammation, cancer progression, fibrosis, and cellular aging. This gene expression “reset” signature has drawn comparisons to the transcriptomic profiles of younger or healthier tissues, fueling significant scientific and commercial interest.
Plasma GHK concentration is approximately 200 ng/mL in healthy young adults and declines significantly with age — to roughly 80 ng/mL by age 60 — a trajectory that some researchers believe may contribute to the age-related decline in regenerative capacity and the increase in inflammatory gene expression that characterizes older tissues. This pharmacoendocrinological context adds biological plausibility to the hypothesis that restoring GHK levels could partially reverse age-associated molecular deterioration.
Browse the full GHK entry in the Peptide Database or use the calculators to design your research protocol parameters.
One of the most mechanistically well-characterized activities of copper-free GHK is its ability to suppress the NF-κB transcription factor system. NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) is a family of transcription factors that, when activated by inflammatory stimuli such as TNF-α, IL-1β, lipopolysaccharide, or reactive oxygen species, translocate from the cytoplasm to the nucleus and drive the expression of dozens of pro-inflammatory mediators including IL-6, IL-8, COX-2, iNOS, and multiple matrix metalloproteinases. In aging and chronic disease, NF-κB activity becomes constitutively elevated — a state that amplifies tissue damage, impairs repair, and contributes to the “inflammaging” phenotype characteristic of biological aging. GHK appears to interfere with NF-κB pathway activation through at least two mechanisms: reduction of IκB kinase (IKK) activity (preventing IκB phosphorylation and NF-κB nuclear translocation) and direct modulation of the chromatin accessibility at NF-κB binding sites in target gene promoters. The result is a broad reduction in inflammatory gene transcription without the immunosuppression associated with corticosteroids or broad cytokine blocking agents, potentially representing a more nuanced anti-inflammatory pharmacology.
Fibrosis — the excessive deposition of extracellular matrix components that progressively stiffens and dysfunctions tissues — is driven primarily by TGF-β1 acting on fibroblasts and myofibroblasts. TGF-β1 activates Smad2/3 transcription factors that drive expression of collagens (particularly type I and III), fibronectin, tenascin, and PAI-1, creating a self-reinforcing fibrotic program. GHK has been shown to suppress this program by reducing TGF-β-induced Smad3 phosphorylation and target gene transcription. Notably, GHK also activates matrix metalloproteinase expression in a controlled manner — specifically MMP-1 (collagenase-1) and MMP-2 (gelatinase A) — which promotes physiological ECM remodeling and turnover rather than pathological accumulation. This dual action — suppressing fibrotic gene expression while promoting productive matrix remodeling — suggests GHK could modulate the fibrosis-repair balance in a direction favorable to tissue organization. Research in skin fibroblast models and lung fibrosis models has been most extensive, though the pattern of TGF-β modulation is likely relevant across fibrosis-prone tissues including liver, kidney, and heart.
Perhaps the most mechanistically novel aspect of copper-free GHK’s biology is its activation of p63 — a transcription factor in the p53 family that is essential for the self-renewal, proliferation, and identity maintenance of epithelial stem and progenitor cells. Unlike p53 (which primarily drives cell cycle arrest and apoptosis in response to DNA damage), p63 (particularly the ΔNp63α isoform) functions as a survival and stemness factor: it maintains the proliferative capacity of basal epithelial cells in skin, lung, breast, and bladder, and its loss leads to premature differentiation and epithelial atrophy. The observation that GHK activates p63 expression provides a mechanistic framework for GHK’s well-established promotion of wound reepithelialization and its ability to stimulate hair follicle activity. It also connects GHK to broader stem cell biology: if GHK can activate ΔNp63α in tissue-resident progenitor cells, it may help maintain the “stemness” reserve that tissues need for effective regenerative responses. Whether GHK activates p63 through a defined receptor-mediated signaling pathway or through more direct regulatory interactions with the gene promoter is an area of active investigation.
The most comprehensive characterization of copper-free GHK’s biological effects comes from genome-wide expression studies published by Dr. Loren Pickart and colleagues, who used the Broad Institute’s Connectivity Map (CMAP) and LINCS L1000 databases to analyze the transcriptomic “fingerprint” of GHK across multiple cell lines and treatment conditions. Their analyses found that GHK modulates expression of approximately 4,000 human genes at statistically significant levels — an extraordinarily broad footprint for a tripeptide. The pattern of modulation shows a coherent biological logic: gene ontology analysis reveals enrichment for tissue repair, wound healing, extracellular matrix remodeling, stem cell function, metabolic energy production, and anti-oxidative defense among upregulated genes, while downregulated gene sets are enriched for inflammation, metastasis, cancer progression, fibrosis, and DNA damage response to genotoxic stress. The researchers noted that this gene expression signature substantially overlaps with patterns seen in young, healthy tissue compared to aged or diseased tissue, and they proposed that GHK may function as a systemic signaling molecule that communicates tissue damage and drives a coordinated regenerative response across the organism — a “damage signal” with a built-in repair instruction.
Cross-referencing the GHK gene expression signature against curated databases of cancer-related gene expression revealed a striking anti-metastatic profile. GHK downregulates a substantial portion of the genes associated with the metastatic cascade — specifically genes involved in epithelial-mesenchymal transition (EMT), focal adhesion assembly and turnover, matrix metalloproteinase production and activation, chemokine receptor expression that guides metastatic homing, and angiogenic remodeling that supports metastatic tumor vascularization. In cell culture studies using breast cancer, lung cancer, and melanoma cell lines, GHK treatment has been associated with reduced cell migration and invasion assay performance, reduced MMP-9 secretion in pro-metastatic conditions, and partial reversal of EMT markers. Whether these findings translate to in vivo anti-tumor activity is not established — the transcriptomic evidence is compelling but mechanistic cell culture work and animal model studies would be needed before any therapeutic extrapolation. Importantly, GHK’s simultaneous pro-proliferative effects through p63 and stem cell pathways mean the net effect in a tumor context requires careful model-specific investigation.
GHK’s activation of p63 and related epithelial stemness genes has direct implications for research in stem cell biology and tissue engineering. Studies in keratinocyte and epidermal progenitor cell models have shown that GHK treatment increases the proportion of cells expressing basal stem cell markers (integrin α6, p63, keratin 14) and enhances the clonogenic capacity of epidermal progenitors — their ability to form colonies in soft agar assays, a functional measure of stem cell self-renewal. In wound healing models, GHK accelerates reepithelialization and promotes the organized layering of the regenerating epidermis, consistent with coordinated stem cell activation followed by appropriate differentiation. Research in hair follicle models shows GHK stimulates follicular keratinocyte proliferation and maintains the anagen (active growth) phase, consistent with engagement of the follicular stem cell compartment in the bulge region. These findings suggest GHK could be a valuable tool for ex vivo stem cell culture optimization and potentially for in vivo applications where preservation of epithelial progenitor capacity is therapeutically desirable.
A particularly intriguing application of GHK gene signature analysis was the comparison against COPD expression databases. Chronic obstructive pulmonary disease involves progressive inflammation, protease-mediated alveolar destruction (emphysema), airway fibrosis, and impaired mucosal repair — a constellation of pathological gene expression changes that mirror, in many respects, the inverse of what GHK produces. Pickart and colleagues analyzed the GHK gene signature against published COPD airway epithelium expression datasets and found remarkable complementarity: a substantial fraction of the genes most upregulated in COPD airways are downregulated by GHK, and vice versa. This in silico complementarity does not prove therapeutic efficacy, but it provides a principled bioinformatic rationale for designing GHK intervention studies in COPD models — a hypothesis-generating finding that warrants formal animal model testing. Given the significant unmet need in COPD pharmacotherapy and the compound’s tolerability profile in topical applications, this is a research direction with potentially high value.
GHK — in both copper-containing and copper-free forms — has one of the more extensive experimental literatures in wound healing among research peptides. Topical and subcutaneous GHK (and GHK-Cu) application has been studied in full-thickness punch biopsy wound models in rodents, where it consistently accelerates wound closure rate, increases granulation tissue formation, and promotes more organized collagen deposition compared to vehicle controls. The copper-free contribution to these effects has been difficult to isolate in most studies because the majority of wound healing research has used GHK-Cu. However, mechanistic studies using GHK without copper in keratinocyte and fibroblast cell culture models demonstrate GHK’s ability to stimulate keratinocyte migration, fibroblast proliferation, and TGF-β modulation in ways that collectively support the wound repair response, independent of copper’s antioxidant chemistry. Clinical research using GHK-containing topical formulations in humans has shown improvements in skin elasticity, dermal thickness, and wound healing rates in controlled trials, though isolating the GHK-specific vs. copper-specific contribution remains methodologically challenging in those clinical settings.
Copper-free GHK’s neuroprotective gene expression signature has attracted interest in the context of neurodegenerative disease research. Analysis of GHK’s transcriptomic effects in neural cell models reveals upregulation of genes encoding neurotrophic factors (BDNF, NGF, NT-3), synaptic scaffolding proteins, and components of the ubiquitin-proteasome system that clears misfolded proteins. Simultaneously, GHK suppresses gene programs associated with neuroinflammation (NF-κB targets in microglia and astrocytes) and mitochondrial dysfunction. In rodent models of spinal cord injury and peripheral nerve damage, systemic GHK administration has been associated with improved functional recovery and reduced inflammatory infiltration at injury sites. The mechanistic contribution of copper-free GHK to these effects versus copper-dependent mechanisms requires careful dissection, but the breadth of the neuroprotective gene signature provides compelling preclinical rationale for further investigation in neurodegeneration models.
GHK and GHK-Cu research studies have used a wide range of doses depending on route and model. In cell culture models, GHK typically produces gene expression changes and functional effects in the nanomolar to micromolar concentration range (1 nM–10 µM). In topical formulations for skin models, concentrations of 0.1–5% by weight have been used. For subcutaneous and systemic delivery in rodent models, doses ranging from approximately 1 to 50 mg/kg have been reported in the wound healing literature. Because copper-free GHK is a tripeptide with a molecular weight of 340 Da, it is rapidly cleared from plasma (half-life estimated in the range of minutes to a few hours), so systemic dosing frequency matters significantly for sustained tissue exposure. Use the Peptides Helper calculators for dose modeling.
GHK has been studied via topical, subcutaneous, intraperitoneal, and intravenous routes. Topical application has the strongest clinical literature (primarily for skin, wound, and hair applications) and the most favorable safety profile. Systemic delivery has been used in animal models for neurological, pulmonary, and anti-inflammatory applications where topical delivery is impractical. Given GHK’s small size and relative hydrophilicity in its free form, skin penetration from topical formulations can be enhanced with penetration enhancers or nanoparticle carrier systems. The peptide’s ability to enter cells and modulate nuclear gene expression in the copper-free form has been confirmed, though the precise transport mechanism from extracellular space to the nucleus is not fully characterized.
For researchers specifically interested in the gene regulatory and NF-κB/TGF-β modulating properties of GHK, using the copper-free form avoids potential confounds from copper’s own redox biology, antioxidant chemistry, and angiogenic effects. Copper-free GHK is appropriate for studies designed to isolate peptide-specific transcriptional effects. GHK-Cu is more appropriate for studies focused on wound angiogenesis, collagen maturation, or conditions where the oxidative environment is a primary variable. Many commercially available GHK preparations for research are supplied as the acetate salt of the free tripeptide without copper, but researchers should confirm the copper content of their material by ICP-MS or similar analytical method before use in copper-free mechanistic studies.
Copper-free GHK is hygroscopic and should be stored as a lyophilized powder under desiccation conditions, ideally at −20°C. It dissolves readily in aqueous buffers and saline at physiological pH. Solutions for cell culture work should be prepared fresh or stored at −20°C in single-use aliquots to avoid repeated freeze-thaw cycles. For in vivo use, sterile saline solutions are standard. The peptide is generally stable at physiological pH and temperature for the duration of typical biological assays (hours) but should not be left in solution at 37°C for multi-day periods without stability verification.
GHK (predominantly as GHK-Cu) has a long track record in topical cosmetic and wound care products in humans, with a generally excellent tolerability profile. Contact sensitization is rare, and systemic adverse events attributable to topical GHK have not been reported in clinical literature. Copper toxicity from topical GHK-Cu is considered minimal at cosmetically relevant application amounts due to the low absolute dose and limited transdermal flux. The copper-free GHK tripeptide lacks the copper-related variables entirely, and no topical adverse events specific to copper-free GHK have been reported in the published literature.
GHK’s pro-proliferative effects through p63 activation and stem cell pathway stimulation raise a theoretical consideration in oncological contexts: could GHK stimulate growth of pre-existing epithelial tumors? This question has not been systematically addressed in the published literature. The anti-metastatic gene expression signature and the suppression of EMT and invasion-associated genes suggest that, if anything, GHK might reduce the aggressiveness of existing tumors rather than promote growth — but this is speculative. The NF-κB suppression itself tends to have anti-tumor effects in inflammation-driven malignancies. The net effect in any specific tumor type would depend on the balance of GHK’s pro-stemness and anti-inflammatory/anti-metastatic gene regulatory effects in that particular cancer biology. Until dedicated carcinogenicity studies are available, caution is warranted when considering GHK use in the context of known or suspected neoplasia.
While topical GHK (as GHK-Cu) has extensive real-world human safety data from cosmetic use, systemic administration of copper-free GHK in humans has not been studied in formal clinical trials. The compound’s modulation of thousands of genes across multiple biological systems means that systemic delivery could have wide-ranging effects that are difficult to predict from focused cell culture or animal model studies alone. Comprehensive toxicology studies including sub-chronic and chronic administration, reproductive toxicity, and genotoxicity assessment are lacking in the published literature for systemically administered copper-free GHK. Researchers should consult the AI Coach for current literature on GHK safety endpoints and study design guidance.
GHK is the free tripeptide glycyl-L-histidyl-L-lysine. GHK-Cu refers to the same tripeptide coordinated with a copper(II) ion, typically at the histidine imidazole nitrogen and the terminal amino group. GHK-Cu has additional biological activities conferred by the copper coordination — particularly superoxide dismutase-like antioxidant activity, facilitation of copper delivery to enzymes like lysyl oxidase (which crosslinks collagen and elastin), and VEGF-mediated angiogenic promotion. Copper-free GHK retains the peptide’s intrinsic gene regulatory activities but lacks copper’s redox chemistry. For research focused specifically on transcriptional and gene regulatory mechanisms, using the copper-free form isolates the peptide-specific effects.
This is a reasonable and important scientific question. The answer lies in the hierarchy of transcriptional regulation: GHK does not interact directly with all 4,000 gene promoters individually. Instead, it modulates the activity of master transcription factors — particularly NF-κB, TGF-β/Smad pathway components, and p63 — each of which has hundreds of downstream target genes. When you suppress NF-κB, you simultaneously reduce expression of dozens of inflammatory genes. When you activate p63, you upregulate large gene networks associated with stem cell renewal. GHK also appears to interact with chromatin regulatory proteins and possibly directly with certain gene regulatory sequences. The network effects of modulating a small number of master regulatory nodes can propagate to thousands of downstream targets, which is why a small peptide can produce a genome-wide transcriptomic footprint.
The gene expression data showing overlap between GHK’s transcriptomic signature and “younger” gene expression patterns is genuinely interesting and scientifically preliminary. It would be premature to say GHK “reverses aging” based on transcriptomic analysis alone — gene expression changes do not automatically translate to functional cellular rejuvenation, and many compounds can shift gene expression profiles without producing meaningful physiological change. What can be said is that GHK’s pattern of gene regulation — reducing inflammatory and fibrotic gene expression while upregulating repair, stem cell, and metabolic genes — is consistent with gene expression patterns associated with better tissue health. Whether this has meaningful physiological consequences in aging tissues requires longitudinal functional studies that have not yet been completed at the level of rigor needed for strong conclusions.
GHK is a tripeptide that will be partially hydrolyzed in the gastrointestinal tract. However, tripeptides are somewhat more resistant to complete hydrolysis than larger peptides, and some absorption of intact GHK across intestinal epithelium via peptide transporters (PEPT1/PEPT2) has been proposed. The oral bioavailability of GHK has not been formally characterized with pharmacokinetic studies, and it is likely substantially less than 100%. Some researchers have used enteric-coated formulations or sublingual delivery to mitigate gastrointestinal degradation. For systemic research applications where precise dosing and delivery verification are required, parenteral routes are generally preferable to oral delivery.
In healthy young tissue, GHK is proposed to function as part of the tissue damage signaling system — released from albumin and other plasma proteins following injury to signal that repair is needed and to coordinate a regenerative response. At the circulating concentrations found in healthy young adults (~200 ng/mL), GHK may serve a constitutive homeostatic function in maintaining baseline stem cell activity and suppressing chronic low-level inflammatory signaling. The decline in plasma GHK with age may be one component of the broader decline in regenerative reserve observed in aging organisms, though this remains a theoretical framework rather than an established causal relationship.
There are no published studies systematically examining GHK combinations with other research peptides. Theoretically, combining GHK with peptides that act through complementary mechanisms (e.g., BPC-157 for vascular/gut repair, Thymosin beta-4 for cytoskeletal remodeling and cardioprotection) could be interesting given their non-overlapping mechanisms. However, combination pharmacology adds considerable complexity to interpreting experimental results, and researchers should establish individual compound effects before moving to combinations. The AI Coach can help design appropriate multi-compound research frameworks.
The GHK measured in human plasma is predominantly present as the free tripeptide and in complex with albumin, from which it can be released by proteolytic activity at sites of tissue damage. A portion of plasma GHK is likely coordinated with copper given the copper-binding affinity of the histidine residue, but the free tripeptide form also exists. Research-grade copper-free GHK peptide replicates the free tripeptide form found in plasma. Ensuring that the research reagent is genuinely copper-free (confirmed by ICP-MS) is important for mechanistic studies that seek to attribute observed effects specifically to the peptide rather than to copper coordination chemistry.
Disclaimer: This information is for research and educational purposes only. It is not medical advice. Consult a qualified healthcare professional before using any peptide.